Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

COX-2 Advisory Committee May Decide Fate of Pfizer’s Bextra

Executive Summary

The commercial future of Pfizer's Bextra may be at stake during FDA's early 2005 advisory committee discussion of the COX-2 inhibitor class

You may also be interested in...



Merck May Need New Arcoxia Trial Design Prior To FDA Approval

Merck may need to conduct additional Arcoxia clinical trials to gain FDA approval after the agency and its COX-2 inhibitor advisory committee cited flaws in the existing program

Merck May Need New Arcoxia Trial Design Prior To FDA Approval

Merck may need to conduct additional Arcoxia clinical trials to gain FDA approval after the agency and its COX-2 inhibitor advisory committee cited flaws in the existing program

FDA Issues Caution On COX-2s, But Leaves Open Possibility For First-Line Use

FDA's caution on the use of COX-2 inhibitors leaves open the possibility for patients to use Pfizer's Celebrex and Bextra as first-line therapies

Related Content

UsernamePublicRestriction

Register

OM011995

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel